Log in to search using one of your social media accounts:

 

Two Anti-VEGF Agents Shine in DME Trial
(MedPage Today) -- Bevacizumab lags in three-way comparison (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - February 13, 2018 Category: Primary Care Source Type: news

Combo Bests Targeted Agent in mRCC
(MedPage Today) -- Improved PFS with first-line atezolizumab and bevacizumab pairing (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - February 7, 2018 Category: Hematology Source Type: news

Phase III IMmotion151 study showed Roche's TECENTRIQ ® (atezolizumab) and Avastin® (bevacizumab) reduced the risk of disease worsening or death by 26 percent in certain people with advanced kidney cancer
Roche today announced results from the positive Phase III IMmotion151 study of TECENTRIQ ® (atezolizumab) and Avastin® (bevacizumab) as a first-line treatment for advanced or metastatic renal cell carcinoma (mRCC). (Source: Roche Media News)
Source: Roche Media News - February 6, 2018 Category: Pharmaceuticals Source Type: news

Phase III IMmotion151 study showed Roche's TECENTRIQ ® (atezolizumab) and Avastin® (bevacizumab) reduced the risk of disease worsening or death by 26 percent in certain people with advanced kidney cancer
Roche today announced results from the positive Phase III IMmotion151 study of TECENTRIQ ® (atezolizumab) and Avastin® (bevacizumab) as a first-line treatment for advanced or metastatic renal cell carcinoma (mRCC). (Source: Roche Investor Update)
Source: Roche Investor Update - February 6, 2018 Category: Pharmaceuticals Source Type: news

Support for Upfront Immunotherapy in Advanced Renal Cell Cancer Support for Upfront Immunotherapy in Advanced Renal Cell Cancer
Atezolizumab plus bevacizumab improves progression-free survival with greater tolerability than standard sunitinib in advanced kidney cancer in a randomized controlled trial.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 5, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

IV Bevacizumab Effective for Severe HHT - Related Bleeding
Drop in RBC transfusion requirements, epistaxis severity in hereditary hemorrhagic telangiectasia (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - February 5, 2018 Category: Cancer & Oncology Tags: Gastroenterology, Oncology, Pharmacy, Journal, Source Type: news

New and highly sensitive ELISA technique for bioanalysis of bevacizumab
(Bentham Science Publishers) Bevacizumab is an anti-growth factor vascular endothelial growth factor (VEGF) monoclonal antibody, it is the antiangiogenic agent at the most advanced stage of development in the treatment of NSCLC.This drug was selected because of its inter individual differences in clinical response, its therapeutic importance in the treatment of non-small cell lung cancer (NSCLC). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 31, 2018 Category: International Medicine & Public Health Source Type: news

Bevacizumab dramatically improves severe hereditary hemorrhagic telangiectasia (HHT) associated bleeding
(Elsevier) Patients with hereditary hemorrhagic telangiectasia (HHT) with severe bleeding, who were treated with intravenous bevacizumab, reported a marked reduction in nose bleeds and gastrointestinal bleeding and were able to stop or considerably reduce blood transfusions, resulting in significantly improved quality of life. A new study published in Mayo Clinic Proceedings provides good quality evidence for the excellent safety profile and efficacy of intravenous bevacizumab in the management of these patients. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 29, 2018 Category: International Medicine & Public Health Source Type: news

No Survival Benefit with Bevacizumab Maintenance in CRC (CME/CE)
(MedPage Today) -- Monotherapy no better than observation after induction chemo (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - January 28, 2018 Category: Gastroenterology Source Type: news

No Benefit With Bevacizumab Maintenance Therapy for Metastatic CRC During Chemo-Free Intervals
Adding bevacizumab maintenance therapy failed to improve outcomes compared with no treatment when administered during chemotherapy-free intervals to patients with metastatic colorectal cancer after induction chemotherapy. (Source: CancerNetwork)
Source: CancerNetwork - January 25, 2018 Category: Cancer & Oncology Authors: Dave Levitan Tags: Colorectal Cancer Gastrointestinal Cancer News Source Type: news

European Commission Approves Amgen And Allergan's MVASI ® (Biosimilar Bevacizumab) For The Treatment Of Certain Types Of Cancer
Marketing Authorization Based on Global Development Program Showing MVASI is Highly Similar to Avastin® (Bevacizumab) First Biosimilar Bevacizumab Approved in the European Union THOUSAND OAKS, Calif., Jan. 18, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and Allergan plc. (NYSE: AGN) today announced that the European Commission (EC) has granted marketing authorization for MVASI® (biosimilar bevacizumab). MVASI is the first biosimilar bevacizumab approved by the EC and is approved for the treatment of certain types of cancers, including in combination with fluoropyrimidine-based chemotherapy for metastatic ...
Source: Amgen News Release - January 18, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Tumor Microvessel Density as Marker for Bevacizumab Benefit Tumor Microvessel Density as Marker for Bevacizumab Benefit
What are the potential predictive and prognostic effects of these five biomarkers in patients with ovarian cancer?Journal of the National Cancer Institute (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 9, 2018 Category: Consumer Health News Tags: None Journal Article Source Type: news

DelMar Pharma wins fast track status for glioblastoma drug
DelMar Pharmaceuticals (NSDQ:DMPI) said today that the FDA granted its lead product candidate, VAL-083, fast track status for approval as a therapy for recurrent glioblastoma. The designation applies to a Phase II trial with the University of Texas MD Anderson Cancer Center and a Phase III trial in patients whose disease has progressed after treatment with temozolomide and bevacizumab. Get the full story at our sister site, Drug Delivery Business News. The post DelMar Pharma wins fast track status for glioblastoma drug appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - December 29, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Food & Drug Administration (FDA) Neurological Oncology Pharmaceuticals Regulatory/Compliance Wall Street Beat DelMar Pharmaceuticals Source Type: news

Phase III IMmotion151 Study Met Co-primary Goal In Kidney Cancer
The study demonstrated that the combination of TECENTRIQ (atezolizumab) and Avastin (bevacizumab) provided a statistically significant and clinically meaningful reduction in the risk of disease worsening or death...12/12/2017 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - December 12, 2017 Category: Urology & Nephrology Source Type: news

Roche: Tecentriq cocktail slows kidney cancer progression
ZURICH (Reuters) - Combining Roche's Tecentriq immunotherapy with its older drug Avastin reduced the risk of disease worsening or death (PFS) for the initial treatment of advanced kidney cancer in some patients, the Swiss drugmaker said on Monday (Source: Reuters: Health)
Source: Reuters: Health - December 11, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Phase III IMmotion151 study showed Roche ’s Tecentriq (atezolizumab) and Avastin (bevacizumab) reduced the risk of disease worsening or death for the initial treatment of certain people with advanced kidney cancer
Roche today announced that the Phase III IMmotion151 study met its co-primary endpoint of investigator-assessed progression-free survival (PFS) and demonstrated that the combination of Tecentriq ® (atezolizumab) and Avastin® (bevacizumab) provided a statistically significant and clinically meaningful reduction in the risk of disease worsening or death (PFS) in people whose disease expressed the PD-L1 (programmed death-ligand 1: Expression ≥1%) protein compared with sunitinib for the fir st-line treatment of people who have advanced or metastatic renal cell carcinoma (mRCC). (Source: Roche Media News)
Source: Roche Media News - December 11, 2017 Category: Pharmaceuticals Source Type: news

Phase III IMmotion151 study showed Roche ’s Tecentriq (atezolizumab) and Avastin (bevacizumab) reduced the risk of disease worsening or death for the initial treatment of certain people with advanced kidney cancer
Roche today announced that the Phase III IMmotion151 study met its co-primary endpoint of investigator-assessed progression-free survival (PFS) and demonstrated that the combination of Tecentriq ® (atezolizumab) and Avastin® (bevacizumab) provided a statistically significant and clinically meaningful reduction in the risk of disease worsening or death (PFS) in people whose disease expressed the PD-L1 (programmed death-ligand 1: Expression ≥1%) protein compared with sunitinib for the fir st-line treatment of people who have advanced or metastatic renal cell carcinoma (mRCC). (Source: Roche Investor Update)
Source: Roche Investor Update - December 11, 2017 Category: Pharmaceuticals Source Type: news

Phase III IMpower150 study showed Tecentriq (atezolizumab) and Avastin (bevacizumab) plus chemotherapy reduced the risk of disease worsening or death by 38 percent for people with a type of advanced lung cancer
Roche today announced results from the positive, pivotal Phase III IMpower150 study of Tecentriq ® (atezolizumab) and Avastin® (bevacizumab) plus chemotherapy (carboplatin and paclitaxel) in people with previously untreated advanced non-squamous non-small cell lung cancer (NSCLC). (Source: Roche Media News)
Source: Roche Media News - December 7, 2017 Category: Pharmaceuticals Source Type: news

Phase III IMpower150 study showed Tecentriq (atezolizumab) and Avastin (bevacizumab) plus chemotherapy reduced the risk of disease worsening or death by 38 percent for people with a type of advanced lung cancer
Roche today announced results from the positive, pivotal Phase III IMpower150 study of Tecentriq ® (atezolizumab) and Avastin® (bevacizumab) plus chemotherapy (carboplatin and paclitaxel) in people with previously untreated advanced non-squamous non-small cell lung cancer (NSCLC). (Source: Roche Investor Update)
Source: Roche Investor Update - December 7, 2017 Category: Pharmaceuticals Source Type: news

FDA grants Roche ’s Avastin full approval for most aggressive form of brain cancer
Roche announced today that the U.S. Food and Drug Administration (FDA) has granted full approval for Avastin ® (bevacizumab) for the treatment of adults with glioblastoma that progressed following prior therapy (referred to as recurrent disease). (Source: Roche Investor Update)
Source: Roche Investor Update - December 6, 2017 Category: Pharmaceuticals Source Type: news

Poor regulation, dodgy pills spur plan for African drugs agency
LONDON (Reuters) - Last July, Ugandan officials seized fake versions of the cancer drug Avastin on sale in Kampala, revealing only the tip of an iceberg of bogus medicines found all too often in Africa. (Source: Reuters: Health)
Source: Reuters: Health - December 4, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

French Oncologists Upgrade Mesothelioma Standard of Care
Oncologists throughout France have joined the U.S.-based National Comprehensive Cancer Network (NCCN) in upgrading their recommended standard-of-care treatment regimen for unresectable pleural mesothelioma. Both groups have added bevacizumab (Avastin) to the traditional cisplatin and pemetrexed chemotherapy combination, expecting to see longer patient survival. “This is a major advancement for the care of mesothelioma patients,” Dr. Gerard Zalcman, head of thoracic oncology at Bichat-Claude Bernard Hospital, told Asbestos.com. “Clearly, this drug can change the natural history of this tumor.” Bevaci...
Source: Asbestos and Mesothelioma News - November 20, 2017 Category: Environmental Health Authors: Daniel King Tags: American Society of Clinical Oncology Avastin bevacizumab Bichat-Claude Bernard Hospital French Cooperative Thoracic Intergroup Gerard Zalcman National Comprehensive Cancer Network nintedanib Ofev pleural mesothelioma chemotherapy Source Type: news

Phase III IMpower150 study showed Roche ’s TECENTRIQ (atezolizumab) and Avastin (bevacizumab) plus chemotherapy significantly reduced the risk of disease worsening or death in the initial treatment of people with a type of advanced lung cancer
Roche today announced that the Phase III IMpower150 study met its co-primary endpoint of progression-free survival (PFS) and demonstrated that the combination of TECENTRIQ ® (atezolizumab) and Avastin® (bevacizumab) plus chemotherapy (paclitaxel and carboplatin) provided a statistically significant and clinically meaningful reduction in the risk of disease worsening or death (PFS) compared to Avastin plus chemotherapy in the first-line treatment of people with advan ced non-squamous non-small cell lung cancer (NSCLC). Initial observations for the co-primary endpoint of overall survival (OS) are encouraging. These d...
Source: Roche Media News - November 20, 2017 Category: Pharmaceuticals Source Type: news

Phase III IMpower150 study showed Roche ’s TECENTRIQ (atezolizumab) and Avastin (bevacizumab) plus chemotherapy significantly reduced the risk of disease worsening or death in the initial treatment of people with a type of advanced lung cancer
Roche today announced that the Phase III IMpower150 study met its co-primary endpoint of progression-free survival (PFS) and demonstrated that the combination of TECENTRIQ ® (atezolizumab) and Avastin® (bevacizumab) plus chemotherapy (paclitaxel and carboplatin) provided a statistically significant and clinically meaningful reduction in the risk of disease worsening or death (PFS) compared to Avastin plus chemotherapy in the first-line treatment of people with advan ced non-squamous non-small cell lung cancer (NSCLC). Initial observations for the co-primary endpoint of overall survival (OS) are encouraging. These d...
Source: Roche Investor Update - November 20, 2017 Category: Pharmaceuticals Source Type: news

EU Panel Likes Biosimilar Bevacizumab, Other Cancer Agents EU Panel Likes Biosimilar Bevacizumab, Other Cancer Agents
The Committee for Medicinal Products for Human Use has issued a new list of recommendations and rejections for oncology products.International Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 10, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

Amgen And Allergan Receive Positive CHMP Opinion For ABP 215 (Biosimilar Bevacizumab) For The Treatment Of Certain Types Of Cancer
First Avastin® (Bevacizumab) Biosimilar Candidate Recommended for European Approval THOUSAND OAKS, Calif., Nov. 10, 2017 -- (Healthcare Sales & Marketing Network) -- Amgen (NASDAQ: AMGN) and Allergan plc. (NYSE: AGN) today announced that the Commit... Biopharmaceuticals, Oncology, Regulatory Amgen, Allergan, biosimilar, Avastin, bevacizumab (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 10, 2017 Category: Pharmaceuticals Source Type: news

Amgen And Allergan Receive Positive CHMP Opinion For ABP 215 (Biosimilar Bevacizumab) For The Treatment Of Certain Types Of Cancer
First Avastin® (Bevacizumab) Biosimilar Candidate Recommended for European Approval THOUSAND OAKS, Calif., Nov. 10, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Allergan plc. (NYSE:AGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the Marketing Authorization of ABP 215, a biosimilar to Avastin® (bevacizumab). ABP 215 has been recommended for approval for the treatment of certain types of cancer, including in combination with fluoropyrimidine-based chemotherapy for metastatic carcinoma of the colon or rec...
Source: Amgen News Release - November 10, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Review Shows Bevacizumab Has Gained Momentum for Mesothelioma...
The VEGF inhibitor is now part of the standard treatment for pleural mesothelioma in France and a recognized first-line option for American clinicians.(PRWeb November 06, 2017)Read the full story at http://www.prweb.com/releases/2017/11/prweb14884392.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - November 6, 2017 Category: Pharmaceuticals Source Type: news

Taxpayers pay twice for crucial drugs like Avastin | Letters
Big pharma companies are charging over the odds for medicines developed with public funding, writeHeidi Chow andTabitha HaIt is shocking, but not surprising, that big drugs companies are threatening to sue the NHS for using cheaper versions of drugs that could save people from going blind (Drug firms trying to stop cheap eye treatment on NHS, 1 November). Another part of this story is that the two medicines in question – Lucentis (known generically as ranibizumab) and Avastin (bevacizumab) are based on the groundbreaking discovery of monoclonal antibodies, whichwere developed with UK public funding.The NHS itself fun...
Source: Guardian Unlimited Science - November 5, 2017 Category: Science Authors: Letters Tags: NHS Drugs Medical research Science Health Society Pharmaceuticals industry Business Blindness and visual impairment Disability Source Type: news

Policy and regulation stand in the way of NHS use of unlicensed eye injection drug with potential to save millions of pounds
Eye injection drugs recommended by NICE cost the NHS up to £ 447 million annually, but could be replaced by an unlicensed drug, bevacizumab, costing as much as ten times less. Use of the two licensed drugs, ranibizumab and aflibercept, has increased three-fold over the last five years, with some parts of England treating five times as many patients as others. (Source: University of Bristol news)
Source: University of Bristol news - November 1, 2017 Category: Universities & Medical Training Tags: Health, Research; Faculty of Health Sciences, Faculty of Health Sciences, Bristol Medical School, Faculty of Health Sciences, Population Health Sciences; Press Release Source Type: news

Health chiefs facing legal fight over cheaper eye drug
Prescribing Avastin will save the NHS "millions of pounds", health bosses say. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - November 1, 2017 Category: Consumer Health News Source Type: news

Doctors face legal action over use of unlicensed eye drug
They want to prescribe Avastin for wet AMD rather than costlier alternatives Related items fromOnMedica UK patients losing out in access to cancer drugs Drug and Therapeutics Update UK ‘inadequate’ at regulating off-label drugs GMC steps into eye drug row Novartis accused of attempt to derail eye drug trials (Source: OnMedica Latest News)
Source: OnMedica Latest News - November 1, 2017 Category: UK Health Source Type: news

FDA accepts Roche ’s supplemental Biologics License Application for Avastin as a front-line treatment for women with advanced ovarian cancer
Roche announced today that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA) for Avastin ® (bevacizumab) in combination with chemotherapy (carboplatin and paclitaxel), followed by Avastin alone, for the front-line treatment of women with advanced ovarian cancer. (Source: Roche Investor Update)
Source: Roche Investor Update - October 26, 2017 Category: Pharmaceuticals Source Type: news

Mvasi (Bevacizumab-awwb Solution for Intravenous Infusion) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - September 27, 2017 Category: Drugs & Pharmacology Source Type: news

Laser May Be Safer Than Bevacizumab in Babies With Acute-phase ROP Laser May Be Safer Than Bevacizumab in Babies With Acute-phase ROP
Babies with acute-phase retinopathy of prematurity (ROP) who are treated with bevacizumab have more long-term eye problems than babies treated with laser, according to a new randomized controlled trial done in Italy.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 18, 2017 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Amgen and Allergan ’s anti-cancer biosimilar Mvasi receives FDA approval
The US Food and Drug Administration (FDA) has approved Mvasi (bevacizumab-awwb) for the treatment of five types of cancer. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - September 17, 2017 Category: Pharmaceuticals Source Type: news

FDA has approved biosimilar of Roche's Avastin
Amgen Inc. AMGN, -1.37% and Allergan AGN, -1.08% said Thursday that the Food and Drug Administration has approved their biosimilar version of Roche's Avastin for five types of cancer.09/15/2017 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - September 15, 2017 Category: Urology & Nephrology Source Type: news

Mvasi Is First Biosimilar Drug Approved for Cancer
Similar to Avastin (Source: Cancercompass News: Other Cancer)
Source: Cancercompass News: Other Cancer - September 15, 2017 Category: Cancer & Oncology Source Type: news

FDA Approves First Biosimilar Drug for Cancer
Mvasi (bevacizumab - awwb) is biosimilar to Avastin (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - September 15, 2017 Category: Cancer & Oncology Tags: Gastroenterology, Gynecology, Internal Medicine, Nephrology, Oncology, Pharmacy, Pulmonology, Institutional, Source Type: news

Mvasi Is First Biosimilar Drug Approved for Cancer
Similar to Avastin (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - September 14, 2017 Category: Cancer & Oncology Tags: Oncology, Pharmacy, FDA Approvals, Source Type: news

FDA Approves Mvasi (bevacizumab-awwb), a Biosimilar to Avastin
September 14, 2017 -- The U.S. Food and Drug Administration today approved Mvasi (bevacizumab-awwb) as a biosimilar to Avastin (bevacizumab) for the treatment of multiple types of cancer. Mvasi is the first biosimilar approved in the U.S. for the... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - September 14, 2017 Category: Drugs & Pharmacology Source Type: news

FDA Approves Amgen And Allergan's MVASI ™ (bevacizumab-awwb) For The Treatment Of Five Types Of Cancer
Approval Based on Totality of Evidence From Global Development Program Showing MVASI™ is Highly Similar to Avastin® (bevacizumab) First Ever Biosimilar to Fight Cancer Approved by FDA THOUSAND OAKS, Calif., Sept. 14, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and Allergan plc. (NYSE: AGN) today announced that the U.S. Food and Drug Administration (FDA) has approved MVASI™ (bevacizumab-awwb) for all eligible indications of the reference product, Avastin® (bevacizumab). MVASI is the first anti-cancer biosimilar, as well as the first bevacizumab biosimilar, approved by the FDA. MVASI i...
Source: Amgen News Release - September 14, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

First Oncology Biosimilar Approved in US: Bevacizumab First Oncology Biosimilar Approved in US: Bevacizumab
The FDA has approved the first biosimilar for use in the treatment of cancer: Myasi, or bevacizumab-awwb (equivalent to Avastin).News Alerts (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 14, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

Mvasi Is First Biosimilar Drug Approved for Cancer
THURSDAY, Sept. 14, 2017 -- The first biosimilar drug to treat cancer has been approved by the U.S. Food and Drug Administration. Mvasi (bevacizumab-awwb) was found to be biosimilar to the anti-cancer drug Avastin, the FDA said Thursday in a news... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - September 14, 2017 Category: General Medicine Source Type: news

U.S. FDA approves biosimilar version of cancer drug Avastin
(Reuters) - The U.S. Food and Drug Administration said on Thursday it has approved Amgen Inc's biosimilar version of Roche Holding AG's cancer drug Avastin. (Source: Reuters: Health)
Source: Reuters: Health - September 14, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Avastin Clone OK'd
(MedPage Today) -- Biosimilar for bevacizumab approved for various cancers (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - September 14, 2017 Category: American Health Source Type: news

FDA approves first biosimilar for the treatment of cancer
The U.S. Food and Drug Administration today approved Mvasi (bevacizumab-awwb) as a biosimilar to Avastin (bevacizumab) for the treatment of multiple types of cancer. Mvasi is the first biosimilar approved in the U.S. for the treatment of cancer. (Source: Food and Drug Administration)
Source: Food and Drug Administration - September 14, 2017 Category: American Health Source Type: news

FDA OKs First'Biosimilar' Drug to Fight Cancer, Mvasi
THURSDAY, Sept. 14, 2017 -- The first approval of a biosimilar drug to treat cancer was announced Thursday by the U.S. Food and Drug Administration. Mvasi (bevacizumab-awwb) was approved as a biosimilar to Avastin (bevacizumab) for the treatment of... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - September 14, 2017 Category: General Medicine Source Type: news